Proliferative and apoptotic fractions of tumors were evaluated in 41 dogs with lymphoma for prediction of response to chemotherapy. All dogs had advanced clinical stage tumors, were untreated prior to study, and received identical induction-remission chemotherapy. Tumor cell proliferation was determined in all pretreatment biopsy specimens and in 18 specimens collected at the time of clinical relapse from remission. Quantitative measures included mitotic index and immunoreactivities for proliferating cell nuclear antigen (PCNA) and Ki-67. Apoptotic index was evaluated from 40 dogs pretreatment and from 16 dogs at the time of first relapse. Pretreatment tumor values for Ki-67, PCNA, and apoptosis were compared with posttreatment values. The median first relapse-free interval (RFI) and overall survival (OS) time were 174 days and 445 days, respectively. Of the proliferation markers, only the results of the Ki-67 analysis were predictive for duration of the first RFI but not OS. Pretreatment apoptotic index was also predictive of the duration of first RFI but not OS. No significant predictive value for comparison of the pretreatment and postrelapse values was demonstrated. Ki-67 labeling index and apoptotic indexes were combined to form both a proliferation/apoptotic ratio (PAR) and a sum, or turnover index. Only the PAR was predictive for duration of first RFI on multivariate analysis. Other variables that were evaluated for their influence on treatment outcome included patient age, weight, gender, clinical stage, clinical substage, and tumor immunophenotype. Of these variables, only immunophenotype was found to be of value for predicting duration of first RFI and OS. From the University of California-Davis, School of Veterinary Medicine, Davis, CA 95616. Current address (Phillips): the University of Wisconsin-Madison, School of Veterinary Medicine, 2015 Linden Drive West, Madison, WI 53706.
Lymphoma is one of the most common neoplasms of the dog. The annual incidence rate has been estimated at 24 cases per 10,000 dogs. 31 The majority of tumors are categorized histologically as intermediate or high grade and phenotypically as B cell. 17, 36 Systemic chemotherapy results in 75-85% complete response rate with median survival times of approximately 1 year. 17, 37 Qualitative factors used to predict responses to chemotherapy for dogs with lymphoma include clinical stage and substage, tumor immunophenotype, and histologic grade. 9, 36, 37 Although these factors allow separation of dogs into groups, it remains difficult to predict treatment responses and survival times for individual dogs with lymphoma. Quantitative measures of cellular proliferation have been tested in canine malignancies as prognostic indicators. The frequency of argyrophilic nucleolar organizer regions (AgNors) in tumor cells was predictive of the duration of first relapse-free interval (RFI) and overall survival (OS) for dogs with lymphoma given chemotherapy. 37 Proliferating cell nuclear antigen (PCNA) was predictive for remission duration in dogs with mammary cancer. 27 Tumor growth is determined by three principal factors: cell cycle time, the percentage of proliferating cells, and the amount of cell loss. The aims of this study were to determine whether cellular proliferative or apoptotic indexes could be used as prognostic factors for dogs with lymphoma subsequently given chemotherapy and whether these quantitative measures correlated with traditional qualitative variables such as tumor histology.
Materials and methods
Animals and specimens. Dogs with histologically confirmed multicentric lymphoma examined between January 1995 and January 1997 at the University of California Veterinary Medical Teaching Hospital were eligible. Dogs previously given anti-neoplastic chemotherapeutic agents, including corticosteroids, were excluded. A biopsy specimen was obtained from all dogs; most biopsies were obtained with a 14-gauge, 2-cm biopsy needle. a Biopsy specimens were examined histologically, and the tumor grade was assigned by the working formulation classification as adapted to the dog. 7 Immunohistochemistry was done to determine immunophenotype. Additional laboratory tests included complete blood count, serum biochemical profile, abdominal ultrasonography, thoracic radiography, and bone marrow aspiration and cytology. With the use of these data, clinical stage and substage were ascribed to each dog by a previously described scheme (World Health Organization). A second biopsy specimen of a peripheral lymph node was collected from 18 dogs at the time of first clinical relapse or at the time of tumor progression.
Biopsy specimens were fixed in 10% neutral buffered formalin for 24 hr prior to embedding into paraffin blocks. Sections were made from the paraffin blocks 1 wk or less before immunohistochemical procedures. All dogs were given identical induction chemotherapy. 28 Determination of remission status was made 6 wk after treatment onset. Complete response was defined as disappearance of all palpable tumor and clinical signs; partial response was defined as 50% or greater decrease in the size of peripheral node(s); no response was defined as less than 50% reduction in the size of peripheral node(s). Nonresponders were excluded from subsequent study. At the time of clinical relapse or progressive disease, dogs were given various antineoplastic drugs.
Laboratory methods. Immunohistochemistry for immunophenotyping for B and T lymphocytes was performed on 4-m serial paraffin sections by the labeled streptavidin biotin-horseradish peroxidase system as previously described with the following modifications: 30 primary antibodies used included monoclonal antibodies to human CD79a for B lymphocytes (1:15), b canine CD45RA or leukocyte common antigen (1:10), c and rabbit polyclonal anti-human CD3 for T cells (1:500). d Sections were pretreated before primary incubation with microwave-induced boiling for 20 min in citrate buffer (pH 6.6) e for the CD79A and CD45RA antibodies and 0.1% trypsin f in 0.1% calcium chloride/Tris buffer (pH 7.6) for 20 min at 37 C for the CD3 antibody. Proliferative fractions were determined by mitotic index and immunohistochemistry for PCNA and Ki-67. The mitotic index was done on 5-m-thick hematoxylin and eosin-stained tissues by counting the percentage of mitoses within 500 cells. PCNA was detected on 4-m-thick tissue sections mounted on poly-L-lysine-coated slides with mouse anti-human monoclonal antibody g diluted 1:400 and incubated at 4 C for 24 hr. A streptavidin-biotin-alkaline phosphatase h and fast red chromagen i system was used following the manufacturers' instructions. The slides were washed liberally in running distilled water after the chromagen reactivity was detected, counterstained with Mayer's hematoxylin j for 30 sec, and mounted in aqueous-based mounting medium. k For Ki-67, antigen retrieval was performed with pretreatment as described for CD79a and CD45RA above. The primary anti-body was mouse anti-human Ki-67 l at 1:80 dilution incubated at room temperature for 1 hr. The detection system was the same as for PCNA ( Fig. 1 ). Positive tissue control was normal lymph node; lymph node follicles were considered sites of proliferation. Negative controls were prepared by omitting the primary antibody and substituting mouse myeloma correlate or purified rabbit IgG.
Apoptotic cells were identified with in situ terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling m (Fig. 2 ). Five-micrometer-thick sections were labeled within 1 wk of cutting. Tissue sections were deparaffinized, fixed, and treated with proteinase K according to the manufacturer's instructions. A nucleotide mixture (45 l of equilibration buffer, 5 l of nucleotide mix [containing fluorescein, for green color], and 1 l of TdT enzyme) was applied to each slide. One microliter of distilled water was used in place of the TdT enzyme in the nucleotide mixture for the negative control (normal lymph node) slide. The slides were incubated for 1 hr at 37 C in a humidified chamber. The slides were washed twice for 5 min each in phosphate-buffered saline (PBS), counterstained with propidium iodide (1 g/ml in PBS) for 15 min, and washed twice for 5 min each in deionized water. One drop of antifade solution n was added to the slides and a coverslip was applied. The edges were sealed with clear nail polish.
Quantitative methods. Quantitation of proliferative cells was done by light microscopy, whereas for apoptosis, a fluorescent microscope o and computerized image scanning system p were used. For all microscopic determinations, five adjacent, nonoverlapping fields were selected at random and examined with a 64-square (8 ϫ 8) ocular grid and 400ϫ magnification. For specimens in which positive cells were not diffusely distributed, counts were made in the regions of most intense staining. One hundred cells (PCNA and Ki-67) and 200 cells (apoptotic) were counted from each field for a total of 500 and 1,000 cells per sample, respectively; positive cells were expressed as a percentage of the cells counted. For detection of apoptotic cells, slides were scanned with the fluorescent microscope with 400ϫ power, and the five fields were captured and stored by a computerized image analysis program prior to cell counting. For PCNA, weakly and strongly positive cells were counted separately for each field, and these values were then evaluated individually and in combination in the final statistical analysis.
Ki-67 reactive cells and apoptotic fraction were used to evaluate combined tumor kinetics. A proliferation/apoptotic ratio (% Ki-67 positive cells/% apoptotic cells: PAR) and sum, or ''turnover index'' (% positive Ki-67 cells ϩ % positive apoptotic cells: TI), were determined. Posttreatment samples, when available, were examined similarly to pretreatment samples.
Statistical methods. Survival analyses were used to evaluate the potential effects of risk factors on first remission duration and the rate of death. Censorship was defined as failure to follow the original chemotherapeutic protocol during the period after first remission, no chemotherapy administration after first relapse, lost to follow-up, death during the follow-up period from causes unrelated to neoplastic disease, or remaining clinically disease-free at the end of the study follow-up period.
The effects of age, weight, gender, tumor stage and substage, immunophenotype, histologic grade, and tumor cell kinetic values for PCNA labeling index (LI), Ki-67 LI, mitotic index, apoptotic index, PAR, TI, and pretreatment versus posttreatment values for PCNA, Ki-67, and apoptosis were analyzed by the product-limit (Kaplan-Meier) method of survival function estimation (to estimate median first remission duration and survival time) and by Cox proportional hazard regression analysis (to estimate univariate and multivariate hazard rate ratios and 95% confidence intervals [95% CI]). Effects of Ki-67 and apoptosis on first remission duration and survival within histologic grade (low, medium, high) were similarly evaluated. The Kruskal-Wallis one-way analysis of variance was used to compare degree of staining for Ki-67 and apoptosis across the three histologic grades.
Variables with P-values less than 0.05 were considered statistically significant. Potential risk factors with P-values Ͻ 0.25 were further considered for inclusion into multivariate Cox proportional hazards regression models.
Results
Forty-one dogs were evaluated for influence of gender, age, weight, stage, and substage on first RFI and OS. Four dogs were censored from first RFI analysis and 14 dogs from OS analysis (lost to follow-up, one RFI, one OS; no relapse or alive, one RFI, five OS; failure to follow protocol, two RFI, six OS; and death due to causes other than tumor, zero RFI, two OS). Thirty-seven (90.2%) dogs attained complete remission, and four (9.8%) dogs attained partial remission while receiving the first induction-remission chemotherapy. Median first RFI was 174 days (range 20-680 days) and median OS was 455 days (range 53-1034 days). None of the patient variables was predictive for either first RFI or OS in multivariate analysis (Table 1) .
Forty-one dogs had pretreatment tumor samples available for evaluation of tumor grade, immunophenotype, mitotic index, PCNA and Ki-67 LIs, and response to treatment. Forty dogs had pretreatment tumor samples available for analysis of apoptotic index, PAR, and TI. Results of these tumor variables and their influence on prognosis are listed ( Tables 1, 2) . Immunophenotype, Ki-67 LI (divided into quartiles), apoptotic index (divided into halves), and PAR (the higher the PAR, the longer the first RFI) were the tumor variables that were significant for duration of first RFI in multivariate analysis. Immunophenotype was the only tumor variable that was significant for prediction of OS in multivariate analysis; dogs with CD3(ϩ) tumors had significantly shorter OS than dogs with CD3(Ϫ) tumors. Eighteen dogs had biopsies collected at the time of first clinical relapse. Two of the posttreatment samples were not available for apoptotic index analysis. Although increased Ki-67 LI at the time of clinical relapse approached significance for prediction of increased OS, there was no difference in OS on the basis of comparison of pre-versus postrelapse indexes for total PCNA or apoptosis. When the tumor kinetic variables were evaluated for their influence on survival within grade (Table 3) , only the mitotic index had a significant effect on survival in multivariate analysis (first RFI and OS, low-grade tumors). As the mitotic index increased, first RFI and OS tended to decrease in duration. When the intermediate-and high-grade tumors were combined (data not shown), apoptotic index was predictive for OS in intermediate-/high-grade tumors (as apoptotic index increased, survival decreased; P ϭ 0.037, multivariate analysis). The mitotic index was predictive for both first RFI and OS in low-grade tumors with a multivariate model. In this model, as mitotic or apoptotic index increased, duration of first RFI and OS decreased. When the absolute values for tumor kinetic variables within grades were compared, there was a significant difference in the mitotic index between low-, intermediate-, and high-grade tumors; low-grade tumors had a significantly lower mitotic rate compared with intermediate-and high-grade tumors ( Table 4 ). There was a trend toward higher PCNA LI and Ki-67 LI in high-grade tumors as well. However, a wide range of values was found for each of these variables within each grade. No difference was apparent in the apoptotic index between tumor grades.
Discussion
Tumor growth kinetic markers (Ki-67 LI, apoptotic index, mitotic index, and PAR) were identified that allowed prediction of response to chemotherapy in some dogs with lymphoma. In this study, mitotic index and immunohistochemistry (PCNA, Ki-67) were used to evaluate the proliferative fraction of small, clinically procured specimens. Mitotic index provides a measure of cells in the M-phase of the cell cycle. PCNA is a nonhistone nuclear protein involved in DNA synthesis as a cofactor for DNA-polymerase-delta. It is highly conserved evolutionarily and detects cells that are dividing because it is expressed in G 1 , S, G 2 , and M phases of the cell cycle. 2, 16 Ki-67 is another highly conserved nonhistone nuclear protein that has a role in maintenance of DNA structure during mitosis. 32 It is expressed in G 1 , S, and G 2 phases of the cell cycle, proliferating canine cells have been shown to express Ki-67. 14, 16 The introduction of the MIB-1 antibody allowed detection of the antigen in formalin-fixed, paraffin-embedded tissues. 8, 29 PCNA and Ki-67 have both been used as markers of cellular proliferation in canine tumors. 18 For dogs with lymphoma, Ki-67 expression correlated with histologic grade. 15 Immunohistochemical measures of cellular proliferation may provide numeric attributes of tumors that portend prognosis, but this technology has limitations. One obstacle is that intratumoral proliferation heterogeneity may confound numeric interpretations, and this may be most important when the clinical specimen is small. Heterogeneous staining of clinical specimens is less of a problem with lymphoma, however, than with other solid tumors because of the diffuse distribution of tumor cells in lymphoma. Most biopsy specimens examined in this investigation showed immunoreactive cells diffusely scattered throughout the specimens. Another impediment is small sample size. Although most biopsy specimens used herein were collected with 14-gauge needles, the specimens allowed nonoverlapping counts of 500 or more cells, which is considered the minimum number of cells required to assure an approximate 4% margin of error with a 95% CI. 5, 26 Fixation time influences PCNA immunoreactivity. 19 To obviate this possible pitfall, the specimens used were fixed for 24 hours in neutral buffered formalin and then processed to paraffin wax. PCNA and Ki-67 staining procedures were done as previously described for canine tissues after formalin fixation. 18 Mitotic index was shown to be predictive of OS within some histologic grades of lymphoma, although a direct correlation of mitotic index with OS for all specimens was not identified. Mitotic index is a relatively inexpensive and easy laboratory method, but it has limitations because of inconsistency in interpretation depending on section thickness, experience of the observer, and the phenomenon of continued mitotic activity in the excised specimen prior to fixation. 12, 13, 33 A trend was found toward correlation of Ki-67 LI with histologic grade (high-grade tumors were associated with higher Ki-67 LI).
Ki-67 LI, but not PCNA LI, was predictive of prolonged RFI but not OS for dogs with lymphoma after onset of chemotherapy. These results may be reflective of increased chemosensitivity of rapidly proliferating tumors when treatment is initiated. Also, although dogs were treated with an identical chemotherapy induction protocol, reinduction protocols varied. That Ki-67 LI and not PCNA LI was predictive of RFI in dogs with lymphoma might reflect differences in these two measures of proliferation. PCNA has a long halflife, and some assays are believed to label cells containing residual PCNA after the cells have exited the cell cycle. 4, 6, 11 PCNA is also involved in DNA repair. Because active DNA repair is ongoing in many tumors, PCNA may be upregulated in nonproliferating cells. 38 In contrast, Ki-67 has a very short half-life, and antibodies to Ki-67 do not label quiescent cells. 6 Further, immunodetection of PCNA is more difficult than for Ki-67 because antibodies to PCNA detect strongly reactive and weakly reactive cells, whereas Ki-67 immunoreactivity is uniform. 4, 6, 18 Apoptotic index also allowed separation of tumor responses to chemotherapy; high apoptotic index was associated with short RFI. Additionally, a high PAR (reflecting a small apoptotic index) was associated with increased duration of first RFI. Simplistically, tumors grow as a consequence of increased cell produc-tion, decreased cell loss, or both. 21 Cell loss from tumors is because of cell migration away from the tumor, cell death, or differentiation of cells. 22 Cell death is because of necrosis or apoptosis. In tumors derived from human patients, wide variation exists in the extent of apoptosis not only between different tumors but also within a tumor type. 34 In one study of human patients with non-Hodgkin's lymphoma, high apoptotic index was associated with high histologic grade and high mortality rate. 25 In several studies, high apoptotic fractions were associated with high proliferation indexes, prompting investigation of combined tumor kinetic variables. [23] [24] [25] When the results of pretreatment analyses were compared with the results of the analyses done on specimens from the same dogs at the time of clinical relapse, only the Ki-67 LI approached significance for prediction of OS. These data suggest that high Ki-67 LI at the time of first diagnosis of lymphoma portends prolonged RFI and that, if the LI is still high at relapse, subsequent treatment response might be expected, leading to prolonged OS. However, clearly OS in dogs with lymphoma given chemotherapy is influenced by many factors not examined herein, particularly for dogs treated over prolonged periods. These factors include, but are not limited to, inherent and acquired drug resistance, concurrent medical problems, variable reinduction protocols, and owner compliance to treatment schedule, suggesting that a clear relationship between any one tumor attribute and OS might remain elusive.
When the proliferative and apoptotic fractions were considered together as a ratio of Ki-67 LI/apoptotic index (PAR), a high ratio was significantly associated with the first RFI by multivariate analysis. The TI (Ki-67 LI ϩ apoptotic index), however, was not predictive of treatment responses. Similar proliferation/apoptosis ratios have been used for analysis of human neoplasms. In one study, tumor kinetic variables were combined in a fashion that demonstrated the predictive value of a novel parameter termed the turnover index (the sum of the mitotic index and apoptotic index). 35 In that study, a group of patients with high-grade non-Hodgkin's lymphoma and with low turnover index had significantly longer overall survival time than the group with high turnover index. It is conceivable that apoptosis and proliferation are coupled and that tumor growth occurs when apoptosis is prevented. 1 A cellular apoptosis susceptibility gene has been identified that initiates apoptosis but is also a proliferation-associated gene. 39 Therefore, if increased proliferation rate is associated with increased expression of this gene, an increased rate of apoptosis may result, but tumor growth and progression may occur if the rate of apoptosis is inadequate to overcome the proliferative fraction.
Quantitative analysis of tumor proliferation is often done by using median cell counts to divide the data into two groups: those above and those below the median value. 10, 20, 37 The use of these arbitrary divisions may not accurately reflect the true biological significance of tumor kinetic markers, and different outcomes might have been obtained with other divisive methods. For example, in one study with AgNors, the use of 8% AgNors within tumors did not predict clinical outcome of dogs with mammary carcinoma treated surgically, whereas the use of 6% AgNors in the analyses allowed prediction of survival times. 3 Neither proliferation nor apoptotic labeling indexes were predictive of OS in dogs studied herein, but if Ki-67 Lis were divided into quartiles, significance was attained for duration of the first RFI in the quartile of dogs with the highest LI. Large groups of dogs with proliferation labeling, apoptotic indexes, and survival data after treatment will be required to allow separation of dogs into biologically significant groups.
In conclusion, this study determined that there is predictive value of tumor kinetic variables (especially Ki-67, apoptotic index, and PAR), used alone or in combination, for dogs with lymphoma given chemotherapy. The results of this study provide rationale for similar investigations of other tumor types to determine whether routine determination of these indexes will be of use in clinical practice. 
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